Shandong Luba Chemical Co.,Ltd
Beijing Multigrass Formulation Co., Ltd.

Arcadia Biosciences to accelerate agricultural trait development with CRISPR-Cas9qrcode

−− Gene editing technology will enable rapid development of nutrition and Ag productivity traits

Sep. 12, 2017

Favorites Print Sep. 12, 2017
Arcadia Biosciences, Inc., an agricultural technology company, announced today that it has signed a global licensing agreement with the Broad Institute of MIT and Harvard for research use of the CRISPR-Cas9 genome-editing technology in agriculture. The technology will enable Arcadia to accelerate the research and development of its agricultural nutrition and productivity traits.

CRISPR-Cas9 works by making precisely-targeted modifications in a cell's DNA, allowing scientists to rapidly enhance beneficial traits or remove undesired plant characteristics. Arcadia will initially focus on applying the technology to speed development of nutritional traits in wheat.

“CRISPR-Cas9 is a high-throughput, cost-effective development tool that is complementary to our ongoing TILLING and transgenic development platforms,” said Raj Ketkar, president and CEO of Arcadia. “We expect this technology will significantly improve the time-to-market for a number of our innovative traits addressing large-acre, high-value crops.”

The Broad Institute is a world leader in the development and sharing of CRISPR genome-editing technologies and holds several issued U.S. patents covering CRISPR-Cas technology. Under the agreement announced today, the Broad Institute grants Arcadia a worldwide non-exclusive research use license for applications of the CRISPR-Cas9 technology in core Arcadia crops. Additional terms of the agreement were not disclosed.

0/1200

More from AgroNews

Magazine

  • 2018 CRO & CRAO Manual 2018 India Pesticide Suppliers Guide
  • 2018 Latin America Focus 2018 Seed Special
  • 2018 Biologicals Special 2018 Formulation & Adjuvant Technology

Subscribe to daily email alerts of AgroNews.